Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations

References

• Rao GG, Konicki R, Cattaneo D, et al. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1): 83–92.
   PubMed Web of Science ®Google Scholar
• Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs. 2001;61(4):525–551.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Malacarne P, Guidotti E, et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet. 2010;49(7):439–447.
   PubMed Web of Science ®Google Scholar
• Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759–1767.
   PubMed Web of Science ®Google Scholar
• Eriksson HK, Ahadpour D, Hailer NP, et al. Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci. Infect Dis (Lond). 2019;51(9):683–690.
   PubMed Web of Science ®Google Scholar
• Chen H, Du Y, Xia Q, et al. Role of linezolid combination therapy for serious infections: review of the current evidence. Eur J Clin Microbiol Infect Dis. 2020;39(6):1043–1052.
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2016;15(1):41.
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285(10):1291.
   PubMed Web of Science ®Google Scholar
• Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517–520.
   PubMed Web of Science ®Google Scholar
• Oehadian A, Santoso P, Menzies D, et al. Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria. Tuberc Respir Dis (Seoul). 2022;85(2):111–121.
   PubMed Web of Science ®Google Scholar
• Patel MI, Makhija SJ. Toxicity assessment of linezolid and the beneficial effects of human erythropoietin in mice. Euro J Exp Biol. 2012;2:2172–2181.
   Google Scholar
• Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis. 2002;35(3):E29–31.
   PubMed Web of Science ®Google Scholar
• Luo Z, Xu N, Wang Y, et al. Linezolid-induced pure red cell aplasia: a case report and literature review. J Int Med Res. 2018;46:4837–4844.
   PubMed Web of Science ®Google Scholar
• Nishijo N, Tsuji Y, Matsunaga K, et al. Mechanism underlying linezolid-induced linezolid-associated thrombocytopenia in a chronic kidney failure mouse model. J Pharmacol Pharmacother. 2017;8(1):8–13.
   PubMedGoogle Scholar
• Tajima M, Kato Y, Matsumoto J, et al. Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol Pharm Bull. 2016;39:1846–1851.
   PubMed Web of Science ®Google Scholar
• Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695–698.
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii45–53.
   PubMedGoogle Scholar
• Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001;21(8):1010–1013.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40(4):839–845.
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–1518.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–1442.
   PubMed Web of Science ®Google Scholar
• Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603–615.
   PubMed Web of Science ®Google Scholar
• Imperial MZ, Nedelman JR, Conradie F, et al. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin Infect Dis. 2022;74(10):1736–1747.
   PubMed Web of Science ®Google Scholar
• Bandín-Vilar E, García-Quintanilla L, Castro-Balado A, et al. A review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet. 2022;61(6):789–817.
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54(4):798–802.
   PubMed Web of Science ®Google Scholar
• Qin Y, Liu Y, Chen Z, et al. A risk factor-based predictive model for linezolid-induced anaemia: a 7-year retrospective study. J Clin Pharm Ther. 2021;46(6):1591–1599.
   PubMed Web of Science ®Google Scholar
• Zyvox (linezolid) injection, tablets, and oral suspension. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf. Accessed Jul 20, 2022.
   Google Scholar
• Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–1078.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Cozzi V, et al. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48:728–731.
   PubMed Web of Science ®Google Scholar
• Tinelli M, Gervasoni C, Piazza M, et al. Is it time to revise linezolid dose in elderly patients? Eur J Clin Pharmacol. 2017;73:1335–1336.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Fusi M, Cozzi V, et al. Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action? Clin Pharmacokinet. 2021;60(5):603–609.
   PubMed Web of Science ®Google Scholar
• Nishi Y, Ogami C, Tsuji Y, et al. Evaluation of the relationship between linezolid exposure and hyponatremia. J Infect Chemother. 2021;27(2):165–171.
   PubMed Web of Science ®Google Scholar
• Dai Y, Wang Y, Zeng Y, et al. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2020;45(6):1422–1426.
   PubMed Web of Science ®Google Scholar
• Cheng CN, Wu CC, Kuo CH, et al. Impact of high plasma concentrations of linezolid in Taiwanese adult patients-therapeutic drug monitoring in improving adverse drug reactions. J Formos Med Assoc. 2020;120(1 Pt 2):466–475.
   PubMed Web of Science ®Google Scholar
• Rodríguez O, Alvarez F, Oltra R, et al. Use of linezolid in critically ill patients admitted to intensive care units. Rev Esp Quimioter. 2009;22(2):68–75.
   PubMed Web of Science ®Google Scholar
• Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029–1035.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee E, Cho YJ, et al. Linezolid-inducedLinezolid-associated thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J Clin Pharm Ther. 2019;44(1):84–90.
   PubMed Web of Science ®Google Scholar
• Maray I, Rodríguez-Ferreras A, Álvarez-Asteinza C, et al. Linezolid induced thrombocytopenia in critically ill patients: risk factors and development of a machine learning-based prediction model. J Infect Chemother. 2022;28(9):1249–1254.
   PubMed Web of Science ®Google Scholar
• Cazavet J, Bounes FV, Ruiz S, et al. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2020;39(3):527–538.
   PubMed Web of Science ®Google Scholar
• Wicha SG, Mair A, Chiriac U, et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Int J Antimicrob Agents. 2022;59(5):106572.
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen Z, Gao S, et al. Development and validation of a risk prediction model for linezolid-induced linezolid-associated thrombocytopenia in elderly patients. Eur J Hosp Pharm. 2022; Epub ahead of print
   PubMedGoogle Scholar
• Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345–351.
   PubMed Web of Science ®Google Scholar
• Soriano A, Ortega M, García S, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother. 2007;51(7):2559–2563.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33(1):98–99.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55(5):1867–1873.
   PubMed Web of Science ®Google Scholar
• Cossu AP, Musu M, Mura P, et al. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol. 2014;70(1):23–28.
   PubMed Web of Science ®Google Scholar
• Shi C, Xia J, Ye J, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):464–475.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–387.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242–247.
   PubMed Web of Science ®Google Scholar
• Kawasuji H, Tsuji Y, Ogami C, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22(1):13.
   PubMed Web of Science ®Google Scholar
• Zuo M, Sun Y, Zhao X, et al. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight. J Clin Pharm Ther. 2022;47(12):2162–2169.
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72.
   PubMed Web of Science ®Google Scholar
• Kato H, Hamada Y, Hagihara M, et al. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy. J Infect Chemother. 2015;21(10):707–712.
   PubMed Web of Science ®Google Scholar
• Kawasuji H, Tsuji Y, Ogami C, et al. Y Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients. Antibiotics (Basel). 2021;10(5):496.
   Google Scholar
• Gervasoni C, Bergia R, Cozzi V, et al. Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother. 2015;70(10):2918–2920.
   PubMed Web of Science ®Google Scholar
• Dou L, Meng D, Dong Y, et al. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients. Int J Infect Dis. 2020;96:105–111.
   PubMed Web of Science ®Google Scholar
• Ikuta S, Tanimura K, Yasui C, et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J Infect Chemother. 2011;17(3):388–391.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Yu W, Zhou N, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid. Hepatobiliary Pancreat Dis Int. 2015;14(3):287–292.
   PubMed Web of Science ®Google Scholar
• Dai Y, Jiang S, Chen X, et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J Clin Pharm Ther. 2021;46(3):807–813.
   PubMed Web of Science ®Google Scholar
• Chen C, Li Y, Yu J, et al. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case-control study. Clin Transl Oncol. 2022;24(3):540–545.
   PubMed Web of Science ®Google Scholar
• Wicha SG, Frey OR, Roehr AC, et al. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. Int J Antimicrob Agents. 2017;50(4):557–563.
   PubMed Web of Science ®Google Scholar
• Alraish R, Wicha SG, Frey OR, et al. Liver function, quantified by the LiMAx test, as a predictor for the clinical outcome of critically ill patients treated with linezolid. Technol Health Care. 2022;30(2):309–321.
   PubMed Web of Science ®Google Scholar
• Zhang SH, Zhu ZY, Chen Z, et al. Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction. Antimicrob Agents Chemother. 2020;64(6):e00133–20.
   PubMed Web of Science ®Google Scholar
• Han X, Wang J, Zan X, et al. Risk factors for linezolid-induced thrombocytopenia in adult inpatients. Int J Clin Pharm. 2022;44(2):330–338.
   PubMed Web of Science ®Google Scholar
• Kaya Kılıç E, Bulut C, Sönmezer MÇ, et al. Risk factors for linezolid-associated thrombocytopeniaì and negative effect of carbapenem combination. J Infect Dev Ctries. 2019;13(10):886–891.
   PubMed Web of Science ®Google Scholar
• Lima LS, Brito EDCA, Mattos K, et al. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. Hematol Transfus Cell Ther. 2020;42(3):230–237.
   PubMedGoogle Scholar
• Cojutti PG, Merelli M, Bassetti M, et al. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. J Antimicrob Chemother. 2019;74(12):3588–3595.
   PubMed Web of Science ®Google Scholar
• Choi GW, Lee JY, Chang MJ, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228–234.
   PubMed Web of Science ®Google Scholar
• Niwa T, Watanabe T, Suzuki A, et al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. Diagn Microbiol Infect Dis. 2014;79(1):93–97.
   PubMed Web of Science ®Google Scholar
• Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58(4):2334–2343.
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Zhao XQ, Shan BZ, et al. Efficacy and safety of linezolid in treating Gram-positive bacterial infection in the elderly: a retrospective study. Indian J Microbiol. 2014;54(1):104–107.
   PubMed Web of Science ®Google Scholar
• Bi LQ, Zhou J, Huang M, et al. Efficacy of linezolid on Gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pak J Med Sci. 2013;29(3):837–842.
   PubMed Web of Science ®Google Scholar
• Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195–206.
   PubMed Web of Science ®Google Scholar
• Minson Q, Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy. 2010 Sep;30(9):895–903.
   PubMed Web of Science ®Google Scholar
• Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–2133.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhang XS, Dai Y, et al. Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients. Front Pharmacol. 2022;13:844567.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726.
   PubMed Web of Science ®Google Scholar
• Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40(3):279–284.
   PubMed Web of Science ®Google Scholar
• Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536–542.
   PubMed Web of Science ®Google Scholar
• Thirot H, Briquet C, Frippiat F, et al. Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers. Antibiotics (Basel). 2021;10(5):530.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36(2):179–181.
   PubMed Web of Science ®Google Scholar
• Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012;44(1):60–64.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–2042.
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–2133.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586–589.
   PubMed Web of Science ®Google Scholar
• Fang J, Chen C, Wu Y, et al. Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study. Ann Transl Med. 2020;8(7):493.
   PubMed Web of Science ®Google Scholar
• Komatsu T, Nakamura M, Uchiyama K, et al. Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia. J Chemother. 2022;34:375–380. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Kokilambigai KS, Lakshmi KS, Sai Susmitha A, et al. Linezolid-A review of analytical methods in pharmaceuticals and biological matrices. Crit Rev Anal Chem. 2020;50(2):179–188.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Tsuji Y, Kasai H, et al. Classification tree analysis based on machine learning for predicting linezolid-induced thrombocytopenia. J Pharm Sci. 2021;110(5):2295–2300.
   PubMed Web of Science ®Google Scholar
• Ogami C, Tsuji Y, Nishi Y, et al. External evaluation of population pharmacokinetics and pharmacodynamics in linezolid-induced thrombocytopenia: the transferability of published models to different hospitalized patients. Ther Drug Monit. 2021;43(2):271–278.
   PubMed Web of Science ®Google Scholar
• Hui LA, Bodolea C, Vlase L, et al. Linezolid administration to critically ill patients: intermittent or continuous infusion? A systematic literature search and review. Antibiotics (Basel). 2022;11(4):436.
   PubMed Web of Science ®Google Scholar
• Abou Warda AE, Sarhan RM, Al-Fishawy HS, et al. Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges. Pharmaceuticals (Basel). 2022;15(3):296.
   PubMedGoogle Scholar
• Mitta A, Curtis BR, Reese JA, et al. Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. Am J Hematol. 2019;94(3):E76–E78.
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775–2780.
   PubMed Web of Science ®Google Scholar
• Crass RL, Cojutti PG, Pai MP, et al. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob Agents Chemother. 2019;63(8):e00605–19.
   PubMed Web of Science ®Google Scholar
• Gatti M, Cojutti PG, Bartoletti M, et al. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Crit Care. 2022;26(1):178.
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015;59(1):178–185.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fang E, Minassian SL, et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014;58(12):7198–7204.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Bidell MR, Flanagan SD, et al. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. J Antimicrob Chemother. 2016;71:2553–2558.
   PubMed Web of Science ®Google Scholar
• Das D, Tulkens PM, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis. 2014;58(Suppl 1):S51–57.
   PubMed Web of Science ®Google Scholar
• Ueda T, Nakajima K, Ichiki K, et al. Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms. J Infect Chemother. 2022;28(7):1023–1028.
   PubMed Web of Science ®Google Scholar